title: Reduction in facial photodamage by a topical growth factor product.
abstract: A topical gel containing a proprietary mixture of over 110 growth factors, cytokines, and soluble matrix proteins secreted by human dermal fibroblasts was evaluated for safety and efficacy in the treatment of mild to severe facial photodamage. In a double-blind study, 60 subjects were randomly assigned to receive either active gel or the vehicle and applied twice daily for 6 months along with a moisturizing cleanser and sunscreen. Efficacy (profilometry, photography, and clinical assessment) and safety (adverse event reporting) measures were evaluated at 0, 3, and 6 months. Treatment with the active gel for 3 months produced greater reduction in fine lines and wrinkles than the vehicle treatment as measured by objective and subjective assessment techniques. The results were either statistically significant (P < or = .05) or trending towards statistical significance (P < or = .1). This study demonstrates that addition of a topical formulation of growth factors and cytokines to a basic skin care regimen reduces the signs of photoaging.
authors.affiliation: SkinMedica Inc, Carlsbad, CA 92010, USA. rmehta@skinmedica.com
authors.forename: Rahul C
authors.initials: RC
authors.lastname: Mehta
authors.forename: Stacy R
authors.initials: SR
authors.lastname: Smith
authors.forename: Gary L
authors.initials: GL
authors.lastname: Grove
authors.forename: Rosanne O
authors.initials: RO
authors.lastname: Ford
authors.forename: William
authors.initials: W
authors.lastname: Canfield
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Donofrio
authors.forename: Timothy C
authors.initials: TC
authors.lastname: Flynn
authors.forename: James J
authors.initials: JJ
authors.lastname: Leyden
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D016207:Cytokines / Q000008:administration & dosage* / Q000009:adverse effects; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects; D004311:Double-Blind Method; D016326:Extracellular Matrix Proteins / Q000008:administration & dosage* / Q000009:adverse effects; D005145:Face / Q000473:pathology; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D005500:Follow-Up Studies; D005782:Gels; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D015595:Skin Aging / Q000187:drug effects*
chemical_list: D016207:Cytokines; D003879:Dermatologic Agents; D016326:Extracellular Matrix Proteins; D005782:Gels; D036341:Intercellular Signaling Peptides and Proteins